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Aims.Anew perspective on autoantibodies as pivotal players in the pathogenesis of type 1 diabetes (T1D) has recently emerged. Our
key objective was to examinewhether increased levels of autoantibodies against the𝛽-cell autoantigens glutamic acid decarboxylase
(isoform 65) (GADA) and insulinoma associated antigen-2A (IA-2A) mirrored the 3.4% annual increase in incidence of T1D.
Methods. From the Danish Childhood Diabetes Register, we randomly selected 500 patients and 500 siblings for GADA and IA-2A
analysis (1997 through 2005). Blood samples were taken within three months after onset. A robust log-normal regression model
was used. Nine hundred children and adolescents had complete records and were included in the analysis. Cochran-Armitage test
for trend was used to evaluate changes in prevalence of autoantibody positivity by period. Results.No significant changes in levels of
GADA and IA-2A were found over our 9-year study period. No trends in autoantibody positivity—in either patients or siblings—
were found. Levels of GADA and IA-2A were significantly associated with HLA risk groups and GADA with age. Conclusion.The
prevalence of positivity and the levels of GADA and IA-2A have not changed between 1997 and 2005 in newly diagnosed patients
with T1D and their siblings without T1D.
1. Introduction
Type 1 diabetes (T1D) is an organ-specific autoimmune
disease, which has a chronic nature and serious long-term
complications [1]. T1D has a strong genetic component and
the cumulative incidence of T1D in monozygotic twins has
been estimated to be 65%, but with latency of onset reaching
decades which suggests an important role of environmental
triggers and/or accelerators in the pathogenesis [2–4]. Alarm-
ingly, many countries, including Denmark, have during
the past few decades experienced an increase in incidence
[5, 6]. Particularly, the rise in onset before the age of 5
years has pointed towards a more aggressive autoimmune
response, for example, caused by an increase in harmful early
environmental exposure [7, 8].
The destruction of 𝛽-cells in the islets of Langerhans is
predominately caused by T-cells, but emerging knowledge
also indicates a pivotal role of B-cells and autoantibodies
[9, 10]. More specifically, autoantibodies form autoanti-
gen-autoantibody complexes; the constant region of the
autoantibodies—in these complexes—then binds to a specific
receptor (crystallizable fragment gamma receptor (FcR𝛾))
found on antigen presenting cells (APCs), resulting in fur-
ther autoantigen presentation by the APCs, hence stimu-
lating the autoimmune response [10]. Furthermore, a more
aggressive type of insulitis (high CD20+ B-cell profile) has
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been identified in human autopsy pancreas samples from
patients with recent-onset T1D before the age of 7 years [11].
Additionally, monoclonal anti-CD20 antibodies (rituximab)
directed against B-cells have been shown to partially halt
𝛽-cell destruction in newly diagnosed patients with T1D
[12]. Whether this effect of rituximab is the cause of cross
talk impairment between T- and B-cells or/and altering
levels of autoantibodies remains to be proven [13]. Therefore,
autoantibodies directed against specific autoantigens in the
pancreas may not only serve as reliable predictors of T1D
development, but may also be active players in the pathogen-
esis of T1D. Furthermore, levels of autoantibodies have been
found to reflect the intensity of the autoimmune response in
patients with T1D and a concurrent autoimmune disease [14].
However, this field of study is currently still in its cradle.
Our key objective was to examine whether increased
levels of autoantibodies—as a proxy of a more aggressive
autoimmune response—against the 𝛽-cell autoantigens glu-
tamic acid decarboxylase (isoform 65) (GADA) and insuli-
noma associated antigen-2A (IA-2A) mirrored the 3.4%
annual increase in incidence of T1D during our 9-year
study period. Furthermore, we wanted to evaluate whether
a temporal trend in autoantibody positivity existed in newly
diagnosed patients with T1D and their siblings without T1D.
Lastly, we wanted to elucidate/replicate whether a set of a
priori defined covariates, that is, case status, gender, season,
and HLA risk, influences the levels of GADA and IA-2A.
2. Materials and Methods
2.1. Design and Sample Population. Data for this study was
derived from a population-based register of children with
T1D. Initiated in 1996, the Danish Childhood Diabetes
Register (DanDiabKids) contains information on more than
5000 newly diagnosed patients aged 0–18 years and has an
associated biobank comprising blood samples from approxi-
mately 75% of all children and their first-degree relatives, of
whom ∼3000 are siblings below 20 years of age. A sample of
500 cases was randomly chosen where blood samples were
taken less than three months after onset. The onset date
was defined as the date of first insulin injection, and T1D
duration thereafter was measured in months. A sample of
500 siblings with similar age and sample year distribution
was chosen. Blood samples from the same family were taken
within one month for 90% of the families. Eighteen patients
and 21 siblings were excluded due to insufficient material for
the study.The patients and siblings chosen are not necessarily
from the same families, but all the siblings included have a
sibling diagnosed with T1D before the age of 18 years [15].
Four hundred and eighty-two patients were included
in the study of whom 255 (52.9%) were males; of the
478 siblings, 266 (55.6%) were males. Eighteen out of 482
patients were immigrants, 13 had unreported ethnicity, and
the remaining were of Danish origin.The ethnicity of siblings
is not reported, but since only siblings with the same father
and mother as the patients are included, the distribution
of ethnicity is the same in the sibling group. The sample
included 203 complete sibships with at least one patient and
onenonpatient, comprising 434 children in total.The sibships
were used to analyse the difference between patients and
siblings.
Serum samples have been stored at −80∘C/−112∘F after
sampling and until usage.
The studywas approved by theDanish Ethical Committee
H-KA-20070009. All procedures followedwere in accordance
with the ethical standards of the responsible committee on
human experimentation (institutional and national) andwith
the Helsinki Declaration of 1975, as revised in 2008.
Informed consent was obtained from all patients or their
parents or guardians for being included in the study.
2.2. Analysis of GADA and IA-2A. GADA and IA-2A were
measured in standard radioligand binding assays [16]. An-
tibody-bound antigen was separated from the free labelled
antigen by Protein A Sepharose and the unbound antigen
was removed by extensive washing. The 97.5% cut-off limits
for GADA and IA-2A positivity were 31 and 5U/mL, respec-
tively. The GADA and IA-2A assays showed mean interassay
coefficients of variation (CV) of 14% and intra-assays CV of
8%. Titration above the value of 500U/mL for GADA and
250U/mL for IA-2A was not performed.
2.3. HLA-DQB1 Genotyping. Time-resolved fluorometry was
used for identification of HLA-DQB1 alleles. This method is
described in detail elsewhere [17].
2.4. Statistical Analyses. The relative change (RC) in IA-
2A and GADA was modeled by robust log-normal regres-
sion taking into account the fact that measurements are
both right and left censored and accounting for correlation
within sibling pairs. GADA measurements are left censored
at 1 U/mL (lower detection limit) and right censored at
500U/mL (upper detection limit). IA-2A measurements are
left censored at 1 U/mL and right censored at 250U/mL. To
account for correlation within sibling pairs, an inference was
based on a working independence generalized estimation
equation (GEE) approach. For both outcomes, the following
risk factors are included in the regression: case status (patient
or sibling), gender, age at sampling (<5, 5–10, and 10+
(years)), season (spring (March throughMay), summer (June
through August), autumn (September through November),
and winter (December through February)), year of sampling
(1997 through 1999, 2000 through 2002, and 2003 through
2005), and HLA-DQB1 genotype (low, moderate, and high
risk) (categorization of genotypes is specified in Table 1).
Estimated RCs in mean are accompanied by Wald 95%
confidence intervals (95% CIs). The 95% CIs are calculated
on a log-scale and subsequently back-transformed. 𝑃 values
correspond to Wald tests and are performed on the log-
scale. Cochran-Armitage test for trend (modified version of
Pearson chi-squared test) was used to evaluate changes in
prevalence of antibody positivity (GADA, IA-2A, or both),
in both patients and siblings, over the three defined 3-year
periods. Furthermore, the latter test was also used to evaluate
changes in HLA risk grouping, in both patients and siblings.
Further, we conducted two kinds of sensitivity analyses,
because we wanted to see whether this changed the effect
of period on GADA and IA-2A levels in the adjusted robust
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log-normal regression model—as mentioned above. First,
we stratified on HLA-DQB1∗02 and then HLA-DQB1∗302.
In addition, we also wanted to examine whether the effect
of period on GADA and IA-2A levels was independent of
positivity of the other autoantibody, so a binary GADA and
IA-2A “positivity variable” was constructed and included in
themodels. Second, we stratified individuals on whether they
were above or below the median age.
All 𝑃 values are evaluated at a 5% significance level. Due
to the explanatory nature of this study, no correction for
multiple testing was performed.
Analyses are made in R version 3.2.0 (https://www.r-
project.org/) using the function survreg in the survival
package [18].
3. Results
Complete measurements of GADA and IA-2A were available
for 960 children. Complete records of GADA, IA-2A, and
HLA-DQB1 genotype were available for 900.
Of the 960 children, 71.4% of the patients and 5.7% of
the siblings were GADA positive (>31U/mL), and 66.8% of
the patients and 2.1% of the siblings were IA-2A positive
(>5U/mL). In all, 87.6% of the patients and 6.1% of the
siblings were positive for a minimum of one autoantibody.
Furthermore, 50.6% of the patients and 1.7% of the siblings
were positive for both autoantibodies. For the 900 chil-
dren with complete records, autoantibody-status results were
nearly identical to those stated above.
3.1. Patients and Siblings. Significant higher levels of GADA
and IA-2A were observed in patients compared to siblings:
GADA (RC (95% CI) = 17.71 (14.18; 22.12), 𝑃 < 0.0001) and
IA-2A (RC (95% CI) = 2.20 ∗ 108 (8.29 ∗ 106; 5.83 ∗ 109),
𝑃 < 0.0001).
3.2. Period. We did not observe statistical significant differ-
ences in GADA or IA-2A levels over the three periods in the
adjusted model (Table 2 and Figure 1).
We also performed tests for trend using antibody status
and period, stratified by case status, and none of these tests
were statistically significant (data not shown) (antibody status
by period is seen in Table 1).
3.3. Age and Sex. GADA levels were significantly higher in
the older age groups when compared to the youngest group:
5–10 yrs (RC (95% CI) = 1.62 (1.01; 2.59), 𝑃 = 0.045) and
10+ yrs (RC (95% CI) = 1.92 (1.22; 3.02), 𝑃 = 0.005). No
association was found with levels of IA-2A (Table 2). We
found no differences in levels between girls and boys.
3.4. HLARisk. A low risk resulted in significantly lower levels
of GADA (RC (95%CI) = 0.72 (0.58; 0.90),𝑃 = 0.004). IA-2A
showed a similar pattern for both low risk (RC= 0.030 (0.004;
0.21),𝑃 = 0.0005) andmoderate risk (RC= 0.014 (0.001; 0.15),
𝑃 = 0.0005) (Table 2).
We also performed tests for trend using HLA risk group-
ing and period, stratified by case status, and none of these
tests were statistically significant (data not shown) (HLA risk
groups by period are seen in Table 1).
3.5. Sensitivity Analyses. Two separate analyses restricted
to individuals carrying (1) HLA-DQB1∗02 and (2) HLA-
DQB1∗302 alleles did not show any statistical significant
differences in GADA or IA-2A levels over the three peri-
ods in the adjusted model (data not shown). Furthermore,
stratifying all individuals into above or below the median
age did not result in any statistical significant differences in
GADA or IA-2A levels over the three periods either (data not
shown).
The remaining covariates were not found to be associated
with GADA and/or IA-2A levels (Table 2).
4. Discussion
First and foremost, our results show no sign of changes in
levels of GADA and IA-2A between 1997 and 2005 in patients
with newly diagnosed T1D and their siblings without T1D. In
addition, we did not observe any statistical significant trends
of autoantibody positivity or HLA risk grouping during our
study period. Secondly, we found that levels of GADA and
IA-2A are associated with HLA risk; hence, newly diagnosed
patients with a lower HLA risk have a weaker humoral
autoimmune response against their remaining 𝛽-cells.
Our study is partly in line with the findings by Long
et al. This study found no proof of an increase in GADA
positivity that concurred with the increasing incidence of
T1D in the UK (1985–2002), but the study found a temporal
increase in IA-2A positivity [19]. The discrepancy in IA-2A
findings between our studies may have two explanations:
(1) ethnicity (hence, differences in the genetic make-up, that
is, non-HLA risk loci, have been associated with IA-2A
positivity) and (2) differences in statistical approach. Long
et al. had a longer study period, 18 years, which rendered a
higher possibility of detecting small temporal changes. The
analytical approach used by Long et al. though does not
use information on the actual autoantibody values above
detection only whether they are positive or negative. As a
consequence, less information can be extracted with their
analytical approach [20–22]. In vitro studies have proven that
higher levels of GADA could enhance autoreactive T-cell
responses and thereby initiate and/or fuel an autoimmune
response [23]. We cannot rule out the notion that this is also
the case in vivo, but no temporal changes in GADA levels
were observed in the present study or prior mentioned study
[19]. Interestingly, emerging evidence indicates that anti-
idiotypic antibodies (anti-Id) can neutralize autoantibodies
and downregulate their production. Anti-Id binds to the vari-
able region (idiotype) on autoantibodies and hereby forms
immune complexes, which are not detected by standard
radioimmunoassays [24, 25]. We have not examined levels
of anti-Id, but since we find no change in levels of GADA or
IA-2A it seems that two scenarios could be possible; that is,
levels of anti-Id have not changed during our study period
or increased levels of anti-Id mask increased levels of GADA
and IA-2A.However, it has to bementioned that the existence
and/or role of anti-Id are still debated [26].
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Table 2: Estimated relative differences in autoantibody levels according to the covariates in the adjusted model.
Outcome Variable Level RC (95% CI) 𝑃 value
GADA
Status Patient 17.71 (14.18; 22.12)
∗ <0.0001
Sibling 1
Gender Females 1.12 (0.91; 1.38) 0.29
Male 1
Age
10+ yrs 1.92 (1.22; 3.02) 0.005
5–10 yrs 1.62 (1.01; 2.59) 0.045
0–5 yrs 1
Period
2003–2005 0.87 (0.70; 1.09) 0.23
2000–2002 1.04 (0.76; 1.42) 0.82
1997–1999 1
Season
Spring 1.12 (0.85; 1.48) 0.41
Summer 0.91 (0.69; 1.21) 0.53
Autumn 0.89 (0.66; 1.22) 0.47
Winter 1
HLA risk
Low 0.72 (0.58; 0.90) 0.004
Moderate 1.39 (0.96; 2.01) 0.083
High 1
IA-2A
Status Patient 2.20 ∗ 10
8 (8.29 ∗ 106; 5.83 ∗ 109) <0.0001
Sibling 1
Gender Females 0.24 (0.06; 1.07) 0.06
Male 1
Age
10+ yrs 3.43 (0.24; 48.11) 0.36
5–10 yrs 6.39 (0.42; 97.17) 0.18
0–5 yrs 1
Period
2003–2005 0.68 (0.13; 3.56) 0.97
2000–2002 1.05 (0.10; 10.72) 0.65
1997–1999 1
Season
Spring 0.69 (0.09; 5.55) 0.73
Summer 2.38 (0.26; 21.39) 0.44
Autumn 0.34 (0.04; 2.93) 0.33
Winter 1
HLA risk
Lowa 0.030 (0.004; 0.21) 0.0005
Moderateb 0.014 (0.001; 0.15) 0.0005
Highc 1
∗Bold letters indicate significance at a 5% level.
HLA-DQB1 genotypes are collapsed into risk categories, which are seen below.
aHLA-DQB1 ∗allele 1/∗allele 2: 06 : 02/03 : 02, 06 : 02/02, 06 : 03/99 : 99, 03 : 01/99 : 99, 06 : 02/03 : 01, 06 : 03/03 : 01, 06 : 04/03 : 01, 06 : 03/02, 03 : 04/99 : 99,
03 : 04/02, 06 : 02/03 : 04, 99 : 99/99 : 99.
bHLA-DQB1 ∗allele 1/∗allele 2: 03 : 01/02, 06 : 03/03 : 02, 02/99 : 99, 06 : 04/02, 06 : 04/99 : 99, 03 : 01/03 : 02. 06 : 04/03 : 04.
cHLA-DQB1 ∗allele 1/∗allele 2: 03 : 02/99 : 99, 03 : 02/02, 06 : 04/03 : 02.
99 : 99 = remaining alleles.
Presentation of T1D shows a bimodal pattern with peaks
at 5–7 years of age and near puberty [1]. We find a positive
association betweenGADA levels and age, whichmay suggest
that GADA plays a more important role in the pathogenesis
of T1D in adolescents and hence may reflect different disease
mechanisms. But this result could also be a result of a larger𝛽-
cell mass and hence stronger stimulation of the autoimmune
response, but interestingly we do not find an age effect for IA-
2A.
We also found that high-risk HLA-DQB1 alleles are
associated with increased levels of both GADA and IA-2A in
the adjusted model. It seems plausible that altered binding
affinities of processed 𝛽-cell autoantigens presented by the
HLA-DQ molecule—due to differences in the genetic make-
up—result in both qualitative and quantitative differences
in autoantibody production, which have also been found
previously [20, 21, 27, 28].
In short, our study benefits from multiple strengths.
Our study is relatively large, and it is population-based and
patients are thoroughly validated. Our results are limited
by only having GADA and IA-2A measurements at one
time point—it would of course have been preferable if
multiple measurements existed during the prediabetic phase.
Furthermore, zinc transporter autoantibodies (ZnT8A) and
6 International Journal of Endocrinology
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Figure 1: Combined box and scatter plots for GADA and IA-2A levels by period and stratification by patient status. Schematic box plots are
only used in the patient stratum, due to no visual graphical gain when used in the sibling stratum, due to low levels of the two autoantibodies.
insulin autoantibodies (IAA) were not measured and we
were therefore not able to evaluate whether positivity for >2
autoantibodies showed temporal changes, but we measured
two of the most common autoantibodies in T1D [28].
In sum, the prevalence of positivity and the levels of
GADA and IA-2A have not changed between 1997 and 2005
in newly diagnosed patients with T1D and their siblings
without T1D. Furthermore, we found no sign of genetic
drift in HLA-DQB1 genotypes during the same period. Our
data indicates that GADA may be more important in T1D
pathogenesis above the age of 5 years.
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